Regulating Formularies: OIG Wants Closer Scrutiny of Process; CMS Says Focus on Results
This article was originally published in RPM Report
Executive Summary
The HHS Inspector General is concerned about lax oversight of conflict-of-interest standards on formulary committees for Medicare Part D plans. CMS is defending its approach, which emphasizes review of the formularies themselves, rather than the process to construct them. For biopharma companies, the “right” regulatory model for formulary oversight is an important issue as health care reform evolves.
You may also be interested in...
A Balancing Act: The Politics of Formularies
Medicare Part D relies on formularies to keep costs down and delivery highquality care to beneficiaries. It also revives a long history of political pressure to keep formularies as open as possible.
Medicare P&T Committees Can Consider Costs, But Only In Broad Context
Medicare prescription drug plan pharmacy & therapeutics committees must consider the overall economic impact of coverage decisions - not just pharmacy costs - if they use pharmacoeconomic data in their analyses, the Centers for Medicare & Medicaid Services states in its final rule implementing Title I of the Medicare Modernization Act
P&T Committees Would Be Powerful Force Under Medicare Rx
The recommendations of pharmacy & therapeutics committees would be binding on Medicare prescription drug plans under the proposed implementing regulations for the Part D benefit